Wall Street is expecting lower profit for Teva Pharmaceutical Industries when the company reports its second quarter results on Thursday, August 1, 2013. Analysts are expecting earnings per share of $1.18 after the company booked a profit of $1.28 a share a year earlier.
The consensus estimate has dipped over the past three months from $1.22. Analysts are projecting earnings of $5.04 per share for the fiscal year. Analysts look for revenue to decrease 1% year-over-year to $4.94 billion for the quarter, after being $4.99 billion a year ago. For the year, revenue is expected to come in at $20.15 billion.
Revenue has declined in the past two quarters. In the first quarter, revenue was $4.90 billion, 2% lower than the year-ago figure. In the quarter before that, revenue fell 8%.
Competitors in the healthcare sector include:
Earnings estimates provided by Zacks.
Narrative Science, through its proprietary artificial intelligence platform, transforms data into stories and insights.
